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Purpose: To determine whether gene polymorphisms of the major genetic risk factor for age-related macular susceptibility
2 (ARMS2 A69S) and the complement factor H Y402H influence the response to a variable-dosing treatment regimen
with ranibizumab for age-related macular degeneration.
Methods: This prospective cohort study included 90 patients (90 eyes) with exudative age related macular degeneration
(AMD) treated with ranibizumab. Patients underwent a 1-year treatment as in the Study of Ranibizumab in Patients with
Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Mitchell et al.). Injections
were administered monthly when a patient lost five letters on the Early Treatment Diabetic Retinopathy Study chart or
gained 100 μm in central subfield retinal thickness (CSRT). Genotypes (rs10490924 and rs1061170) were analyzed using
gene sequence analysis. Best-corrected visual acuity (BCVA) and CSRT values were compared between ARMS2 and
complement factor H genotypes. Multiple regression analysis was used to assess the statistical significance.
Results: Mean increase in visual acuity was 4.44±8.12 letters with a 103.63±94.7 µm decrease in CSRT. BCVA
improvement was statistically significant in all genotype groups except in homozygous 69S in the AMRS2 gene. CSRT
and BCVA changes were correlated (r=0.2521; 95% CI: 0.04746–0.4364, p=0.0165). Multiple regression analysis
revealed a significant impact of 69S (p=0.015) on the change in BCVA.
Conclusions: Visual acuity did not improve during the study in patients homozygous for ARMS2 69S, despite a decrease
in CSRT. Further investigation is needed to confirm our findings and understand the mechanisms involved.
The  complement  factor  H  (CFH)  and  the  age-related
macular susceptibility 2 (ARMS2) variants Y402H and A69S
are major genetic risk and progression factors in age-related
macular  degeneration  (AMD)  [1].  The  CFH  protein  is
responsible  for  regulating  the  complement  alternative
pathway,  which  based  on  the  significant  number  of  risk-
modifying  single  nucleotide  polymorphisms  (SNPs)
identified among protein cascade genes in AMD, is crucially
involved in the etiology of AMD [2]. The role of ARMS2 has
not been fully elucidated; however, some findings suggest that
it is involved in the extracellular matrix [3]. Due to strong
linkage  disequilibrium  between  ARMS2  and  HtrA  serine
peptidase 1 (HTRA1; a serine peptidase gene) and the equal
contribution of their variants (rs11200638 and rs10490924) to
AMD, these genes are usually mentioned together [4].
AMD  remains  a  leading  cause  of  legal  blindness  in
developed countries [5]. Vascular endothelial growth factor
(VEGF) inhibition via injection of anti-VEGF monoclonal
antibodies (e.g., bevacizumab and ranibizumab) has become
the gold standard for AMD treatment in the last decade based
on findings from the MARINA and ANCHOR studies [6,7].
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Questions raised about the costliness and safety of monthly
intravitreal injections of ranibizumab, however, have led to
the search for new prognostic factors. Increasing the period
between treatments decreases the rate (0.05% per injection)
of endophthalmitis, one of the most common and potentially
vision damaging complications [8].
Ranibizumab  inhibits  all  VEGF  isoforms,  and  thus,
improves the efficacy of VEGF treatment [6,7]. The VEGF
121 isoform, however, is a neurotrophic factor and the long-
term effects of its inhibition are not known [8]. Different
regimens have been investigated in an effort to avoid potential
complications and optimize outcomes. Evidence to support
the necessity of injections given every month for the first three
months is related to the clear best-corrected visual acuity
(BCVA) benefit during this period [6,7], but the treatment
regimen following this period is a matter of debate. The Study
of  Ranibizumab  in  Patients  With  Subfoveal  Choroidal
Neovascularization  Secondary  to  Age-Related  Macular
Degeneration (SUSTAIN) was one of the most important
multi-centered clinical trials intended to determine if fewer,
carefully timed injections could provide results similar to
those in the MARINA and ANCHOR studies [9]. In addition,
the cost of monthly treatment could be reduced by at least half
if  the  SUSTAIN  criteria  were  applied  to  determine  the
treatment regimen.
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2598Because AMD is a complex disease with a strong genetic
background,  pharmacogenomics  may  allow  for  more
individualized therapy.
The  purpose  of  the  present  study  was  to  determine
whether  gene  polymorphisms  affect  the  response  to  a
variable-dosing  regimen  treatment  with  ranibizumab
(Lucentis,  Genentech/Novartis)  in  patients  with  choroidal
neovascularization (CNV) subsequent to AMD. Gene variants
selected for the study were ARMS2 A69S – rs10490924 and
CFH  Y402H  –  rs1061170.  Their  putative  influence  on
treatment  efficacy  was  previously  reported  in  patients
undergoing photodynamic therapy (PDT) and bevacizumab
treatment  [10–14],  and  the  effects  of  treatment  with
ranibizumab and CFH Y402H have been studied [15]. We
chose variants with the highest contribution to the disease for
the present study.
METHODS
A cohort of 90 consecutive patients (90 eyes; 47 women and
43 men; Caucasians; mean age, 71.62±8.4 years) of the eye
clinic at the OSK Hospital in Katowice participated in the
study.  Active  subfoveal  CNV  subsequent  to  AMD  was
confirmed  with  fluorescein  angiography  (FA)  and  optical
coherence tomography (OCT) at baseline. All patients had
intraretinal cysts or subretinal fluid or both in the fovea. Of
the 90 patients, 74 were not treatment- naïve. Patients were
enrolled  in  the  study  at  least  3  months  after  any  VEGF
inhibitor injection, and 6 months after PDT or intravitreal
triamcinolone.  Subdividing  patients  into  treatment  groups
was  not  possible  due  to  the  large  variety  of  treatment
modalities  they  had  undergone  before  the  study  (PDT,
ranibizumab,  bevacizumab,  pegaptanib,  steroids,  and
combination therapy).
The  study  was  a  1-center,  1-year,  prospective  cohort
study that was performed by a genotype-masked study team
comprised of BCVA and OCT technicians as well as the
treating investigator. Genetic factors were not revealed to the
study  team  until  the  end  of  the  final  follow-up  visit.  All
patients provided written informed consent before any study
procedure was initiated. The study was approved by the Ethics
Committee of the Medical University of Silesia, Katowice,
Poland (NN-6501–158/I/07) and adhered to the tenets of the
Declaration of Helsinki.
In our study, patients with subfoveal CNV subsequent to
AMD  underwent  a  12-month  ranibizumab  treatment.  The
SUSTAIN study criteria were used to determine the need for
reinjection after the first three monthly injections.
Visits were scheduled every month and subjects were
reinjected each time one of the following criteria was met:
–  loss  of  5  letters  on  the  Early  Treatment  Diabetic
Retinopathy Study (ETDRS) charts compared to the highest
number of letters during the first 3 months of the study; and
– gain of more than 100 µm in central subfield retinal
thickness (CSRT) compared to the lowest CSRT during the
first 3 months of the study.
A CSRT value greater than 225 μm was a prerequisite for
reinjection after the first 3 months. A dose of 0.5 mg/0.05 ml
ranibizumab was used for each treatment.
Examinations:  All  patients  underwent  a  thorough
examination  at  baseline,  including  BCVA,  fundus
photography,  FA,  OCT,  slit-lamp  examination,  indirect
ophthalmoscopy, and Goldmann applanation tonometry. The
study visit schedule is shown in Table 1.
Visual acuity was measured at 4 m with the ETDRS charts
by  one  of  two  experienced  testers  after  standardized
refraction.  OCT  Stratus  III,  software  version  4.0.2  (Zeiss
Meditec,  Dublin,  CA)  was  used  to  assess  the  retinal
morphology (Retinal Thickness Map protocol) and CSRT
(Fast  Retinal  Thickness  Map  protocol).  All  scans  were
acquired by the same experienced OCT technician. FA and
fundus  photography  (Visucam  FF450+;  Zeiss)  were
performed and interpreted by an experienced physician (J.P.)
blinded to. Initial neovascular activity, and size and type of
lesion (predominantly classic, minimally classic, occult) were
assessed.
DNA  collection,  isolation,  amplification,  and
sequencing:  DNA  was  isolated  from  dry  blood  samples
collected on FTA® cards (Whatmann, Maidstone, UK). For
DNA isolation, a disc (diameter, 2.0 mm) was punched and
TABLE 1. STUDY VISIT SCHEDULE.
  Visit
Procedure Baseline I-III IV-V VI VII-XI XII
BCVA (ETDRS) +++++ +
Tonometry +++++ +
Slit-lamp examination and indirect ophthalmoscopy +++++ +
OCT +++++ +
FA + - - + - +
Ranibizumab injection - + optional optional optional -
         BCVA – best-corrected visual acuity, ETDRS – Early Treatment Diabetic Retinopathy Study charts, OCT – optical coherence
         tomography, FA – fluorescein angiography.
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2599collected in a sterile microcentrifuge tube. DNA was isolated
using  the  lysis  and  neutralization  solutions  from  the
REDExtract-N-Amp™ Blood PCR Kit (Sigma-Aldrich, St.
Louis, MO) according to the manufacturer’s protocol. For
PCR amplification of the ARMS2 (5′-ATA CCC AGG ACC
GAT GGT AAC-3′ and 5′-AGA GGA AGG CTG AAT TGC
CTA-3′ primer pair) and the CFH (5′-TTG ACT AAT GCC
CAT TAA TAG GAG-3′ and 5′-TTG ATA TTT CTT TTT
GTG CAA ACC-3′ primer pair) allele, the 2X PCR reaction
mix from the same kit was used with 1 μl of DNA sample and
5  pmol  of  each  primer  in  a  25-μl  reaction  mix.  The
amplification  conditions  were  as  follows:  95  °C  initial
denaturation  for  3  min  followed  by  35  cycles  of  94  °C
denaturation  for  10  s,  58  °C  (for  ARMS2)  or  50  °C  (for
CFH) annealing for 20 s, and elongation at 72 °C for 40 s. In
all PCR reactions, a final elongation step was applied at 72 °C
for 7 min. The quality and quantity of the PCR products was
verified on 1% agarose gels by electrophoresis in Tris/borate/
EDTA buffer. Approximately 20 ng of each PCR product was
purified using the ExoSAP-IT® enzyme mix  (GE Healthcare, 
Buckinghamshire,  UK)  according  to  the  manufacturer’s
instructions  and  directly  submitted  for  DNA  sequence
analysis.
Statistics: Baseline differences between genotype groups
were tested (i.e., BCVA, CSRT, type of lesion, area of lesion)
using the Kruskal–Wallis test. BCVA and CSRT before and
after treatment were compared. A Wilcoxon pair test was used
to assess statistical significance. The possible relationship
between baseline factors and both visual acuity and CSRT
change was tested using multiple regression analysis. The
following parameters were taken into consideration: age, sex,
Y402H and A69S polymorphisms, CNV type, BCVA, CSRT,
and lesion area at baseline. The correlation coefficient for
BCVA and CSRT changes was calculated. MedCalc 10.2.0.0
(MedCalc Software bvba, Mariakerke, Belgium) was used for
all analyses.
RESULTS
BCVA  and  CSRT:  The  average  increase  in  visual  acuity
(4.44±8.12  letters)  was  lower  than  that  reported  in  the
MARINA  and  ANCHOR  studies,  with  a  103.63±94.7
decrease in CSRT. CSRT and BCVA changes were correlated
(r=0.2521; 95% CI: 0.04746–0.4364, p=0.0165). We did not
observe significant BCVA improvement in the ARMS2 69S
homozygous group. In patients homozygous for CFH 402H,
the significance of the BCVA change (p=0.04) was lower than
in the Y402H heterozygous and 402Y homozygous groups
(Table 2).
Genotyping: Genotyping results and baseline characteristics
of  the  study  cohort  are  presented  in  Table  2.  Genotype
frequencies of both polymorphisms were in Hardy–Weinberg
equilibrium.
Treatment efficacy factors: A multiple regression analysis
was performed to assess the independency of the SNP as a
factor associated with treatment efficacy. The BCVA, CSRT,
and number of injections are presented in Table 3, and the final
BCVA, CSRT, and number of injections divided by genotype
group are presented in Table 2. Marked values are statistically
significant compared with the baseline value. The multiple
regression analysis results are presented in Table 3 (BCVA,
OCT,  number  of  injections);  this  analysis  revealed  a
significant influence of 69S homozygosity on the treatment
efficacy measured with BCVA change (p=0.015).
R38X:  Sequence  analysis  of  several  ARMS2  loci  in  our
samples revealed the presence of an additional Arg38Opal
(stop) C/T genotype (R38X). The R38X ARMS2 SNP was
present in 16 patients. In seven patients, it coexisted with
A69S SNP on another allele. R38X did not correlate with the
final BCVA or CSRT.
DISCUSSION
This prospective study revealed a correlation between the
ARMS2 genotype and ranibizumab efficacy when injected
according  to  the  SUSTAIN  study  protocol.  Patients
homozygous for the 69S variant showed a poor response,
especially with regard to BCVA; this group was the only
group of patients that did not gain letters on the ETDRS chart.
As  the  function  of  ARMS2  remains  unknown,  there  is
currently no pathophysiological explanation for the influence
of A69S. Although there were no significant effects of CFH
Y402H,  BCVA  improvement  was  relatively  low  in  the
homozygous 402H group (p=0.04). Because the ranibizumab
treatment regimen was not consistently administered to any
of the subjects, the effect of the chosen reinjection criteria
cannot be excluded as an important environmental factor and
possible  bias.  In  a  previous,  retrospective,  9-month
ranibizumab study, patients were treated at the physician’s
discretion [15], which is why the results are not comparable.
The first pharmacogenetic paper on AMD was published
in 2007, in which no significant effects were detected in a
study of 88 patients who had undergone PDT due to AMD
[10].  Subsequent  papers  reported  conflicting  results.
Goverdhan et al. published a study concluding that 402H may
predispose  to  predominantly  classic  lesions,  and  patients
homozygous for 402H (CC) had significantly worse results
after PDT [13]. However, there were only two TT patients
(homozygous for 402Y) that were studied. Furthermore, we
know that patients with this type of CNV tend to respond
better to PDT [16]. Brantley et al. [11] reported that if patients
with  predominantly  classic  lesions  are  subdivided  by
genotype,  CC  and  CT  patients  have  significantly  better
results.  Interestingly,  the  CC  genotype  was  a  negative
prognostic factor in a cohort treated with bevacizumab every
6 weeks [14]. This effect was also observed in a population
treated  with  ranibizumab  [15].  In  our  study,  patients
homozygous for 402H tended to have worse results, but this
effect was not significant. In the previously mentioned study
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2602of treatment with ranibizumab, the CFH genotype seemed to
influence  the  number  of  injections  [15];  however,  in  our
cohort, this effect was not significant, which might be related
to the different retreatment criteria. The present study is the
first to show that the 69S ARMS2 variant in homozygous
subjects  affects  the  response  to  ranibizumab.  Despite  the
reduction in CSRT, BCVA showed no improvement. Thus,
ranibizumab is effective for reducing macular edema, but the
lack of BCVA improvement might be related to structural
changes in the retina, retinal pigment epithelium atrophy, and
the loss of photoreceptors.
The influence of the gene variants may have been altered
if  more  aggressive  criteria  were  chosen  for  determining
treatment frequency.
Despite  the  significant  findings  in  our  study,  a  false
positive association may be as likely, or even more likely than
a true positive when investigating such common alleles [17].
Further studies are needed to validate these results.
Study limitations: 1. Most patients were not treatment-
naïve and had undergone many different treatment modalities
before the beginning of the study.
2. The number of patients was relatively low.
3. False positive associations may be common in such
studies.
The genetic contribution to the variable outcomes in wet
AMD treatment is likely related to many loci. The combined
effects  of  different  variants  and  gene–environment
interactions make it difficult to detect stronger associations.
Single genotypes are likely to explain only a small proportion
of efficacy variation. It is also possible that risk genotypes
only predispose to the development of late stages of AMD,
but do not influence how these late stages progress or respond
to treatment. Large samples and genome-wide analyses rather
than a candidate gene approach might improve the replication
of  genetic  associations  leading  to  the  generation  of
multivariate  predictive  models  and  personalized  therapy.
AMD  has  a  complicated  etiology,  and  therefore,  lifestyle
factors and antioxidant intake should be included in future
multi-centered clinical trials.
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